» Articles » PMID: 29322519

Inactivation of Chikungunya Virus in Blood Components Treated with Amotosalen/ultraviolet A Light or Amustaline/glutathione

Overview
Journal Transfusion
Specialty Hematology
Date 2018 Jan 12
PMID 29322519
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chikungunya virus, a mosquito-borne arbovirus, often co-circulates with the Zika, dengue, and yellow fever viruses in Aedes mosquito-infested areas where cases of arbovirus transfusion-transmitted infections have been reported. Building on past experience to help maintain the availability of safe components during major outbreaks of chikungunya virus in La Reunion, Italy, and Thailand and of Zika virus in the Pacific, the Caribbean, and the Americas, pathogen inactivation is a mitigation strategy to reduce the risk of transfusion-transmitted infection. Inactivation of chikungunya virus was investigated for platelets in 100% plasma using amotosalen/ultraviolet A light, and in red blood cells using amustaline/glutathione.

Study Design And Methods: Platelets in 100% plasma and red blood cells (RBCs) were spiked with chikungunya virus. Infectious chikungunya virus titers were measured in contaminated blood products before and after treatment with amotosalen/ultraviolet A light for platelets in 100% plasma and after treatment with amustaline/glutathione for RBCs. Viral infectivity was quantified by plaque assay.

Results: The mean chikungunya virus infectivity titers before inactivation were 6.50 log plaque-forming units/mL for platelets in 100% plasma and 7.60 log plaque-forming units/mL for RBCs. No infectivity was detected after amotosalen/ultraviolet A light or amustaline/glutathione treatment, corresponding to greater than 6.5 log plaque-forming units/mL and greater than 7.1 log plaque-forming units/mL of inactivation, respectively.

Conclusion: Robust levels of chikungunya virus inactivation were achieved for platelets in 100% plasma and for RBC components. The licensed amotosalen/ultraviolet A light technology and the amustaline/glutathione pathogen-reduction system under development may provide an opportunity for comprehensive mitigation of the risk of chikungunya virus transfusion-transmitted infection by plasma, platelets, and RBCs.

Citing Articles

Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination.

Kumar A, Tiwari A, Kumar S, Biswas A, Singh G, Chatterjee K Asian J Transfus Sci. 2022; 16(1):67-72.

PMID: 36199414 PMC: 9528557. DOI: 10.4103/ajts.AJTS_108_19.


The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs.

Zeng S, Li Y, Zhu W, Luo Z, Wu K, Li X Microorganisms. 2022; 10(7).

PMID: 35889013 PMC: 9317368. DOI: 10.3390/microorganisms10071294.


Mitigating the risk of transfusion-transmitted infections with vector-borne agents solely by means of pathogen reduction.

Stramer S, Lanteri M, Brodsky J, Foster G, Krysztof D, Groves J Transfusion. 2022; 62(7):1388-1398.

PMID: 35726756 PMC: 9541364. DOI: 10.1111/trf.16950.


Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies.

Santa Maria F, Huang Y, Vanlandingham D, Bringmann P Pathogens. 2022; 11(5).

PMID: 35631042 PMC: 9147860. DOI: 10.3390/pathogens11050521.


Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction.

Sow C, Bouissou A, Girard Y, Singh G, Bounaadja L, Payrat J Transfusion. 2022; 62(5):1073-1083.

PMID: 35385146 PMC: 9325390. DOI: 10.1111/trf.16867.